Provident Financial: Fiscal Q3 Earnings Snapshot
On a per-share basis, the Riverside, California-based company said it had net income of 28 cents.
The holding company for Provident Savings Bank posted revenue of $15.3 million in the period. Its adjusted revenue was $10.1 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PROV at https://www.zacks.com/ap/PROV
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
OpenAI's $500 Billion Power Play: Is This the Hottest Deal in Tech Right Now?
OpenAI is weighing a massive secondary stock sale that could push its valuation to around $500 billion, according to people familiar with the matter. The deal still in early discussions would allow current and former employees to cash out some of their shares, with existing investors like Thrive Capital reportedly circling. If completed, this would mark a roughly 67% jump from OpenAI's previous $300 billion valuation tied to a $40 billion raise, one of the largest in private tech history. The move isn't just about rewarding staff it's also a strategic play to retain top talent in the face of fierce poaching from rivals like Meta, which has dangled nine-figure packages to lure researchers away. Warning! GuruFocus has detected 7 Warning Sign with MSFT. The timing is no coincidence. OpenAI recently secured $8.3 billion in a second tranche of that same $40 billion round, which one source said was oversubscribed by about five times. This fresh capital comes as the company doubles down on product and platform expansion. ChatGPT usage is climbing fast reportedly hitting 700 million weekly active users while the app now processes over 3 billion messages per day. OpenAI is also preparing its next major release, GPT-5, which is undergoing internal testing. While no official launch date has been announced, the model is expected to reinforce OpenAI's lead amid growing competition. On the hardware front, the company is moving ahead with a nearly $6.5 billion all-stock acquisition of a device startup co-founded by Apple design veteran Jony Ive. But the company isn't without friction points. Key investors are still in discussions over how OpenAI should be structured going forward including Microsoft (NASDAQ:MSFT), which has poured in more than $13 billion. At the heart of those talks is Microsoft's stake and long-term access to OpenAI's tech, with the current deal set to run through 2030. As OpenAI races to define its next chapter spanning AI platforms, consumer hardware, and employee retention investors are left with a familiar question: how much more upside is still on the table? This article first appeared on GuruFocus. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
19 minutes ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores
CNBC
21 minutes ago
- CNBC
Firefly Aerospace prices shares at $45, above the expected range
Firefly Aerospace priced shares in its IPO at $45 on Wednesday, above its expected range. The Texas-based rocket maker will debut on the Nasdaq Thursday under the ticker symbol "FLY." The offering raised $868 million and values the company at about $6.3 billion. Firefly filed its initial prospectus in July and upped its IPO range this week to $41 to $43 a share, from an initial range of $35 to $39. The space technology sector has seen rising investor interest over the last few years as billionaire investors such as Elon Musk and Jeff Bezos put their money behind SpaceX and Blue Origin, respectively. So far this year, space technology companies Voyager Technology and Karman Holdings have gone public. The broader IPO landscape has also seen major public debuts this year from Figma, CoreWeave and Circle as the market for public offerings reopens following a prolonged drought. Firefly creates lunar landers, rockets and space technology, and won a $177 million contract with NASA last month. Earlier this year, the company successfully landed its lunar lander known as Blue Ghost on the moon. The company has worked with key defense contractors such as Lockheed Martin and L3Harris. Northrop Grumman invested $50 million in Firefly earlier this year. For the quarter that ended in March, Firefly reported a net loss of about $60.1 million, widening from $52.8 million in the year-ago period. Revenue jumped sixfold to $55.9 million from $8.3 million. Its backlogged totaled about $1.1 billion.
